CPI-613 found to weaken AML cells to chemo
NEWARK, N.J.—Data from a Phase 1 trial of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML) was published in a recent online issue of Clinical Cancer Research, Rafael Pharmaceuticals Inc. reported in mid-April. The study sought to assess CPI-613’s safety, efficacy and maximum tolerated dose when combined with cytarabine and mitoxantrone, and found that the compound sensitizes AML cells to chemotherapy. Of 62 patients evaluable for response, the overall response rate was 50 percent, with median survival of 6.7 months. In patients older than 60, the complete response/complete response with incomplete hematologic recovery (CR/CRi) rate was 47 percent with a median survival of 6.9 months, while 46 percent of patients with poor-risk cytogenetics achieved a CR or CRi.